Our first human imaging with [203Pb]PSV359 suggests rapid uptake and sustained retention in multiple cancer types. PSV359 is a novel peptide developed by our in-house discovery team which targets Fibroblast Activation Protein-α (FAP). Imaging was performed by Dr. Ishita Sen’s group at Fortis Memorial Research Institute - India. Further information will be available in upcoming presentations and publications. https://lnkd.in/ePh7Z6Zh #nuclearmedicine #radiopharma #oncology
Perspective Therapeutics
Pharmaceutical Manufacturing
Game-changing therapies that make an impactful difference for cancer patients and the clinicians who treat them.
About us
We develop game-changing therapies that make an impactful difference for cancer patients and the clinicians who treat them.
- Website
-
https://perspectivetherapeutics.com
External link for Perspective Therapeutics
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Type
- Public Company
- Founded
- 2023
- Specialties
- Oncology, Cancer Treatment, Radiopharmaceuticals, and Imaging Technologies & Diagnostics
Employees at Perspective Therapeutics
Updates
-
We're #hiring a new Peptide Chemist in Coralville, Iowa. Apply today or share this post with your network.
-
We're #hiring a new Discovery Lab Organic Chemist in Coralville, Iowa. Apply today or share this post with your network.
-
We're #hiring a new Executive Administrative Assistant in Coralville, Iowa. Apply today or share this post with your network.
-
Perspective Therapeutics is pleased to announce the appointment of Steve Keefe, MD, MSCE, as Senior Vice President, Clinical Development. Dr. Keefe joins us from Merck, where he led global clinical development in gynecologic cancers. His team at Merck was instrumental in advancing groundbreaking therapies, including pembrolizumab, olaparib, and lenvatinib, as well as pioneering combination strategies with earlier-stage compounds. He received his MD from the University of Chicago and completed a fellowship in Medical Oncology at Penn Medicine. His journey in oncology continued as a clinical investigator at the University of Pennsylvania, where he served on the faculty of the School of Medicine. We are confident that Dr. Keefe's broad experience in oncology drug development further strengthens our capabilities in bringing our novel radiopharmaceutical medicines all the way to patients and their families. Join us in welcoming Dr. Keefe to the team! #Radiopharmaceuticals #Oncology
-
We're excited to be attending the 3rd Annual Targeted Radiopharmaceuticals Summit this week! Our CBO, Amos Hedt, will be participating in a panel discussion on Wednesday, July 31, and a seminar on Thursday, August 1, focused on the current state and the future of #radiopharmaceuticals. Learn more at: https://bit.ly/3WrwrcX
-
Perspective’s CB7-Adma Pre-targeting Platform! Host -> CB7-conjugated antibody Guest -> Adma-modified radionuclide Lag time post Host administration -> Flexible (determined by peak Host tumor uptake and clearance) Our best-in-class platform aims to transform a wide range of existing molecules and targets into “radio-ADCs” to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments. Revolutionizing cancer treatment with a new breakthrough approach. https://lnkd.in/eBr3zAT6
-
We're #hiring a new Cleaning Technician in Coralville, Iowa. Apply today or share this post with your network.
-
Central to our #pretargeting platform is the CB7-Adma (host-guest) complex, which is differentiated because of its superior in vivo stability, modularity, and low immunogenicity. Learn more about our licensed platform at https://lnkd.in/eBr3zAT6 $CATX #radiopharma #nuclearmedicine
-
We are excited to welcome Jeff Zhou , PhD, to Perspective Therapeutics as our Director, Intellectual Property! As a registered patent agent with a strong scientific background in oncology, he will be responsible for developing and executing strategies to protect and maximize the value of Perspective’s IP assets.